In 2025, Novartis demonstrated resilience and strategic focus, balancing strong performance in its core franchises with investments in next-generation therapies. Amid competitive pressures and evolving market dynamics, the company advanced its high-impact pipeline while strengthening leadership in immunology, oncology, gene therapy, and ophthalmology.
Key brands such as Cosentyx continued to expand across dermatology and rheumatology, reinforcing Novartis’ immunology leadership. In oncology, therapies like Scemblix and Kisqali sustained momentum through expanded indications, supporting the company’s broader growth objectives. Meanwhile, Kymriah progressed in cell and gene therapy development, and Leqvio extended access in cardiovascular care, highlighting Novartis’ commitment to transformative treatment platforms. Ophthalmology remained a solid contributor, with Beovu maintaining steady demand in vision care.
While 2025 brought challenges including pricing pressures, generic competition, and intensified regulatory scrutiny, Novartis managed to navigate these headwinds through disciplined portfolio management and targeted innovation investments. Strategic collaborations and the use of real-world evidence further reinforced differentiation and adoption across key therapeutic areas.
Looking ahead to 2026, Novartis is expected to build on this foundation by advancing pivotal pipeline programs and driving growth from high-value brands. Greater emphasis on digital innovation, AI-supported discovery, and global access initiatives is anticipated to strengthen both R&D efficiency and patient reach. Operational discipline will remain central, ensuring that resources are aligned with areas of highest impact.
Overall, 2025 positioned Novartis to leverage its scientific leadership while maintaining portfolio strength. With continued focus on innovation, execution, and patient access, the company is strategically prepared to sustain growth, expand its therapeutic impact, and deliver on long-term value creation in 2026 and beyond.
By
